Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. We are a leader in sleep disorders and epilepsy; further developing in movement disorders and PTSD; and focused on hematologic malignancies and solid tumors. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules, biologics, innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information.

Core strategies include the development, manufacturing and sales of the WatchPAT® diagnostic product line based on the biological PAT® signal acquired by the PAT® technology that was proven as a simple, comprehensive, reliable and scalable alternative to airflow and it enables point-of-deployment versatility; and (ii) Total Sleep Solutions – a product that includes a field support organization, partnerships, as well as core and supporting technologies that enable all physicians in general and Cardiologists, in particular, to provide a seamless and full continuum of care to Sleep Apnea patients as part of their care pathway.

In addition, the company has developed and is currently marketing the EndoPAT® system – an endothelial function assessment tool for risk classification used by clinicians, researchers and pharma companies to easily and reliably quantify and track arterial health.